CytoMed Therapeutics Ltd
Business
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company developing proprietary, off-the-shelf cell‑based immunotherapies for cancer and regenerative indications. Its lead and pipeline products include CTM‑N2D (NKG2DL‑targeting CAR‑grafted gamma delta T cells), iPSC‑gdNKT (iPSC‑derived gamma delta NKT cells), CTM‑GDT (allogeneic gamma delta T cells) and CTM‑MSC (umbilical cord‑derived mesenchymal stem cell therapies). Key operations include research, in‑house cGMP manufacturing, licensing and clinical development through its Singapore holding and Malaysian subsidiaries. It conducts R&D and clinical trials in Singapore and Malaysia and pursues collaborations and investigator‑initiated studies across Asia.
Summary from filing dated 2025-04-28
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-3.11M |
| Total assets | $6.21M |
| Total liabilities | $879.8K |
| Stockholders' equity | — |
| Operating cash flow | — |